GRADE profiles

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Quality assessment LEVOFLOXACIN** | | | | | | | **Quality** |
|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** |
| 6 | randomised trials1 | serious2 | no serious inconsistency | very serious3 | serious4 | none | VERY LOW |
|

1 One single arm study; 3 placebo controlled studies; 2 Two studies with lack of blinding, 1 study with unclear outcome assessment and all studies had very short study duration.  
3 Population: healthy volunteers in stead of contacts of MDR-TB patients; Intervention: IV treatment in 3 studies (preventive treatment is oral treatment) and different dosages.  
4 Small sample size, low number of events

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Quality assessment MOXIFLOXACIN** | | | | | | | **Quality** |
|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** |
| 5 | randomised trials | serious1 | no serious inconsistency | serious2 | serious3 | none | VERY LOW |
|

1 Two studies with lack of blinding and all studies had very short study duration; 2 Population: healthy volunteers instead of contacts of MDR-TB patients.  
3 Small sample size, low number of events.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Quality assessment OFLOXACIN** | | | | | | | **Quality** |
|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** |
| 4 | randomised trials1 | serious2 | no serious inconsistency | very serious3 | serious4 | none | VERY LOW |
|

1 One single arm study; 2 placebo controlled studies; 2 One study with unclear outcome assessment and all studies had very short study duration.  
3 Population: healthy volunteers instead of contacts of MDR-TB patients; Intervention: IV and oral treatment, different dosages; 4 Small sample size, low number of events.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Quality assessment RIFABUTIN** | | | | | | | **Quality** |
|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** |
| 2 | randomised trials | very serious1 | no serious inconsistency | serious2 | serious3 | none | VERY LOW |
|

1 Both studies with lack of blinding and all studies had very short study duration; no placebo-controlled studies.   
2 Population: healthy volunteers instead of contacts of MDR-TB patients.  
3 Small sample size, low number of events.